Advertisement
Research Article

A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants

  • Bambang S. Adiwijaya mail,

    bambang_adiwijaya@vrtx.com

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Eva Herrmann,

    Affiliation: Institute of Biostatistics and Mathematical Modeling, Faculty of Medicine, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

    X
  • Brian Hare,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Tara Kieffer,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Chao Lin,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Ann D. Kwong,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Varun Garg,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • John C. R. Randle,

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Christoph Sarrazin,

    Affiliation: Medizinische Klinik 1, J. W. Goethe-University Hospital, Frankfurt am Main, Germany

    X
  • Stefan Zeuzem,

    Affiliation: Medizinische Klinik 1, J. W. Goethe-University Hospital, Frankfurt am Main, Germany

    X
  • Paul R. Caron

    Affiliation: Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America

    X
  • Published: April 15, 2010
  • DOI: 10.1371/journal.pcbi.1000745

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.